Biogen Inc. ($BIIB) Stock Forecast: Down 5.3% Today

What is Biogen Inc.?

Biogen (BIIB) is a biotechnology company specializing in treatments for neurological and neurodegenerative diseases, with a recent focus on expanding its presence in the Alzheimer's market.

Why is Biogen Inc. going down?

BIIB stock is down 5.3% on Jan 14, 2026 20:50

• The downward movement in Biogen's stock is likely due to expected expenses in the fourth quarter related to in-process research and development (IPR&D) and milestone payments, impacting earnings per share.
• Despite introducing Leqembi and exploring new Alzheimer's treatments, the market response is pessimistic towards the predicted financial changes and costs.
• Analysts, including Bank of America Securities' Hold rating, may be influencing the bearish outlook as investors evaluate the company's financial prospects alongside its strategic goals and product advancements.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence

Biogen is focused on expanding its presence in the Alzheimer's market following the launch of Leqembi. The company is anticipating an FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 from its AHEAD 3-45 study, and is actively pursuing next-generation candidates, including a tau-targeting antisense oligonucleotide. Biogen also aims to leverage the infrastructure established during Leqembi's initial launch for future Alzheimer's indications.

https://www.biospace.com/drug-development/jpm26-with-leqembi-launched-biogen-looks-to-expand-alzheimers-presence

Biogen Sees $1.26 Per Share Impact From IPR&D, Milestone Expenses In Q4

Biogen Inc. expects its fourth-quarter 2025 results to include approximately $222 million in acquired in-process research and development (IPR&D), upfront, and milestone expenses on a pre-tax basis. This charge is anticipated to reduce earnings per share by about $1.26. The expenses are related to collaboration and licensing agreements, including upfront payments, milestone payments, premiums on equity securities, and asset acquisitions of acquired in-process R&D.

https://www.nasdaq.com/articles/biogen-sees-126-share-impact-iprd-milestone-expenses-q4

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

C4 Therapeutics (C4T) has announced strategic milestones through 2028, focusing on advancing cemsidomide as a potential best-in-class IKZF1/3 degrader for multiple myeloma. The company plans to initiate two cemsidomide trials in early 2026 and pursue a new discovery strategy for inflammation, neuro-inflammation, and neuro-degenerative diseases using novel targets. C4T reports a strong cash runway extending to the end of 2028, providing funding through key value inflection points for its portfolio.

https://investingnews.com/c4-therapeutics-outlines-strategic-milestones-to-advance-cemsidomide-as-a-potential-best-in-class-ikzf1-3-degrader-and-discovery-strategy-focused-on-novel-targets-in-clinically-validated-pathways/

Biogen sees Q4 IPR&D impacts on EPS by ~$1.26/share

Biogen anticipates that its fourth-quarter results will be impacted by approximately $1.26 per share due to in-process research and development (IPR&D) charges. This financial adjustment will affect the company's earnings per share for the quarter.

https://www.msn.com/en-us/money/companies/biogen-sees-q4-ipr-d-impacts-on-eps-by-1-26-share/ar-AA1UbUiF?ocid=finance-verthp-feeds

Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB)

Bank of America Securities analyst Tim Anderson maintained a Hold rating on Biogen (BIIB) with a price target of $189.00. This rating follows Biogen's reported quarterly revenue of $2.45 billion and net profit of $466.5 million for the quarter ending September 30. Other analysts have offered differing opinions, with Argus Research also issuing a Hold, while Goldman Sachs maintained a Buy rating.

https://www.theglobeandmail.com/investing/markets/stocks/BIIB/pressreleases/37035325/bank-of-america-securities-keeps-their-hold-rating-on-biogen-biib/

Trending Today

XRP ($XRP) Crypto Forecast: Up 5.6% Today

Ethereum ($ETH) Crypto Forecast: Down 5.4% Today

Bitcoin ($BTC) Crypto Forecast: Down 7.9% Today

Silver ($XAG) Commodity Forecast: Down 7.2% Today

Solana ($SOL) Crypto Forecast: Down 11.4% Today

Jupiter ($JUP) Crypto Forecast: Down 17.9% Today

ZCash ($ZEC) Crypto Forecast: Down 16.5% Today

Monero ($XMR) Crypto Forecast: Down 20.5% Today

Copper ($COPPER) Commodity Forecast: Down 5.2% Today

TRON ($TRX) Crypto Forecast: Down 5.1% Today

Biogen Inc. Price History

31.09.2025 - BIIB Stock was up 3.1%

• BIIB surpassed Q3 earnings and revenue expectations, leading to an initial decline in its stock price following the company's reduction of its 2025 EPS forecast.
• The approval from Health Canada for "LEQEMBI®" to treat early Alzheimer's disease likely contributed to the stock's positive movement.
• Analysts highlighting the potential of Biogen's long-term immunology pipeline, particularly after a recent licensing agreement, may have boosted investor confidence in the company.
• The stock's bullish performance can be attributed to a mix of strong financial results, favorable regulatory milestones, and promising developments in Biogen's product pipeline.

30.09.2025 - BIIB Stock was up 2.3%

• Biogen (BIIB) reported impressive Q3 earnings and revenues, surpassing estimates by a significant margin, indicating strong financial performance.
• Health Canada granting authorization for "LEQEMBI®" for the treatment of Early Alzheimer's Disease is a significant milestone for Biogen, boosting investor confidence in the company's Alzheimer's treatment pipeline.
• The licensing agreement with Vanqua Bio to acquire exclusive rights to a preclinical oral C5aR1 antagonist strengthens Biogen's immunology portfolio, highlighting the company's commitment to innovation and expansion in the healthcare sector.
• The positive news surrounding Biogen's financials, advancements in Alzheimer's treatment, and expansion of its immunology pipeline likely contributed to the bullish movement in the stock today.

01.04.2025 - BIIB Stock was up 3.7%

• BIIB stock surged as investors were impressed by the company's strong performance in the first quarter of 2025.
• Despite Sage Therapeutics' disappointing earnings, BIIB's robust financial results and promising outlook for key metrics exceeded Wall Street estimates, driving up the stock price.
• The market reacted favorably to BIIB's Q1 outlook, indicating confidence in the company's ability to deliver solid results and maintain its position as a key player in the biotech industry.
• Overall, BIIB's bullish movement can be attributed to its strong fundamentals and positive market expectations, contrasting with the underperformance of some of its industry peers.

06.04.2025 - BIIB Stock was down 5.1%

• Following its Q1 earnings release, BIIB witnessed a significant decrease in stock value.
• BIIB outperformed earnings projections, posting an EPS of $3.02 compared to the estimated $2.52, and recorded a revenue surge to $2.43 billion, exceeding the expected $2.23 billion.
• Despite the positive earnings outcome, BIIB's stock faced a decline, potentially due to the mixed Q1 performance and the company's downward revision of its EPS guidance for the year.
• The market response to the revised guidance hints at apprehensions regarding future growth and performance, contributing to the bearish movement in BIIB's stock price today.

14.00.2026 - BIIB Stock was down 5.3%

• The downward movement in Biogen's stock is likely due to expected expenses in the fourth quarter related to in-process research and development (IPR&D) and milestone payments, impacting earnings per share.
• Despite introducing Leqembi and exploring new Alzheimer's treatments, the market response is pessimistic towards the predicted financial changes and costs.
• Analysts, including Bank of America Securities' Hold rating, may be influencing the bearish outlook as investors evaluate the company's financial prospects alongside its strategic goals and product advancements.

14.00.2026 - BIIB Stock was down 5.8%

• Biogen expects a significant impact on its fourth-quarter earnings per share due to in-process research and development (IPR&D) charges, leading to a negative investor sentiment.
• Analysts from Bank of America Securities and other firms hold mixed views on Biogen, resulting in differing ratings and price targets that have added to the uncertainty surrounding the stock.
• The European Commission's approval of a high-dose SPINRAZA regimen for spinal muscular atrophy has the potential to strengthen Biogen's investment outlook. However, concerns about managing pricing pressures on high-cost therapies may have influenced the stock negatively.
• The market's response to Biogen's financial adjustments and upcoming drug launches underscores the need to balance innovation with financial performance in the biotech sector, impacting investor sentiment and stock movement.

14.00.2026 - BIIB Stock was down 6.0%

• Today's downturn in BIIB stock is linked to an anticipated impact of about $1.26 per share on earnings due to research and development charges in the fourth quarter.
• Despite efforts to enhance its presence in the Alzheimer's market with product launches and research endeavors, the financial adjustments appear to have dampened investor confidence.
• Contributing to the bearish sentiment could be analyst ratings like the Hold recommendation from Bank of America Securities, creating uncertainty among investors due to varying opinions.
• The stock's negative performance today reflects a market reaction influenced by financial implications and analyst assessments, despite Biogen's ongoing advancements in its pipeline and infrastructure.

04.03.2025 - BIIB Stock was down 5.0%

• BIIB's stock likely dropped due to the positive announcement of its experimental Alzheimer's drug receiving FDA's fast track designation, potentially heightening optimism for its future success.
• Eli Lilly's Alzheimer's drug received a negative assessment from the European Medicines Agency (EMA), indirectly benefitting Biogen by reducing competition in the Alzheimer's treatment sector.
• Investor sentiment appears to favor Biogen over Eli Lilly, given the challenges the latter faces in gaining regulatory approval for its Alzheimer's drug.
• The divergent paths of the two companies in Alzheimer's drug development may have influenced market outlook towards Biogen, contributing to the downward movement in its stock value today.

06.00.2026 - BIIB Stock was up 5.8%

• BIIB stock surged as Bank of America Securities reiterated a Hold rating with a price target of $189.00, indicating stability and potential growth.
• Anticipation of regulatory progress in international markets, especially in China, for their Alzheimer's treatment formulations, like Leqembi, contributed to the positive market sentiment.
• The acceptance of the Biologics License Application for the subcutaneous formulation of LEQEMBI® for early Alzheimer's disease in China by the National Medical Products Administration was a significant catalyst for the stock's rise.
• The market's positive reaction reflects investors' optimism towards BIIB's innovative treatments and potential expansion into new markets, such as China, driving the stock's bullish movement.

01.07.2025 - BIIB Stock was down 6.0%

• Biogen exceeded earnings and revenue projections for Q2 2025, but its stock faced a downward trend.
• Concerns arose over the drop in sales of MS medications, despite the promising growth exhibited by newer drugs like Leqembi and Skyclarys.
• Investors are exercising caution regarding the company's overall prospects, given the balance between declining sales of MS drugs and gains from newer products.
• While the initial market response to the strong earnings and raised forecasts was positive, uncertainties about Biogen's future performance in the competitive pharmaceutical industry may be dampening investor sentiment.

01.09.2025 - BIIB Stock was up 5.1%

• BIIB stock showed significant growth in trading today.
• The approval of "LEQEMBI®" for Early Alzheimer's Disease treatment in China is believed to have influenced the positive market sentiment.
• Although they received a Complete Response Letter from the FDA for a different drug application, the initiation of bullish coverage by analysts may have outweighed this development.
• Favorable analyst coverage and optimistic forecasts for Biogen likely boosted investor confidence and contributed to the stock's upward trajectory.

10.11.2025 - BIIB Stock was down 5.1%

• Biogen's stock saw a bearish trend despite receiving Health Canada authorization for ZURZUVAE, a groundbreaking treatment for postpartum depression. This unexpected market reaction could be due to various factors:
• The after-hours rally in other biotech stocks, driven by new clinical data and FDA designations, might have shifted investor focus away from Biogen temporarily.
• Highlighting Biogen's undervaluation and potential as a bargain could have already been priced in, leading to profit-taking by investors.
• The market might be reacting to the broader sector movements and investor sentiment rather than solely focusing on Biogen's individual achievements in the postpartum depression treatment space.
• Overall, despite the positive news regarding ZURZUVAE, external factors and profit considerations could have influenced the bearish movement in Biogen's stock today.